A Safety and Efficacy Study of DCL-101 Compared to GoLYTELY

Dark Canyon Laboratories

Status and phase: Completed; Phase 2

Conditions: Bowel Preparation Before Colonoscopy

Treatments: Drug: DCL-101 vs Golytely

Study type: Interventional

Funder types: Industry

Identifiers

NCT02910440

DCL-101-201

Details and patient eligibility

About

The primary objective of this Phase 2 Study was to compare the safety of 3 liter(L) and 4 liter(L) split dose DCL-101 to split dose 4L GoLYTELY in patients preparing for colonoscopy, with secondary objectives to assess tolerability and bowel cleansing efficacy.

Enrollment: 46 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or non-pregnant, non-lactating females, 18 to 75 years of age. Females of child bearing potential must have a negative urine pregnancy test prior to randomization, and must use a hormonal (oral, implantable or injectable) or barrier method of birth control throughout the study. Females unable to bear children must have documentation of such in the source records (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since the last menstrual period]).
2. Routine, non-urgent, screening or surveillance colonoscopy is indicated and scheduled.
3. Ability of subject to participate fully in all aspects of this clinical trial, including ability and willingness to swallow capsules.
4. Informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization will be obtained and documented from all subjects prior to the start of any study-specific procedures.

Exclusion criteria

1. Known hypersensitivity or allergy to any of the components of GoLYTELY or DCL-101
2. Actual or suspected ileus, gastrointestinal obstruction or other major structural gastrointestinal disorders, esophageal stricture, gastric retention, bowel perforation, toxic colitis, ischemic colitis, infectious colitis, toxic mega-colon, or inflammatory bowel disease. Diverticulitis within the past 6 weeks
3. Current or former tobacco users
4. Prior colorectal surgery, esophageal surgery, or gastric surgery. This includes colectomy in the past, colostomy, ulcer surgery (antrectomy or pyloroplasty) or bariatric surgery, including lap band or fundoplication
5. Chronic constipation, gastroparesis, esophageal motility disorders or other gut dysmotility disorders
6. Requiring medications that cannot have the administration schedule safely altered to be compatible with bowel preparation
7. Current or history within the past year of any ongoing clinically relevant electrocardiogram abnormalities
8. Clinically significant electrolyte abnormalities during Screening, defined by the range of normal of the central laboratory
9. Significant psychiatric illness
10. Renal failure or chronic kidney disease (creatinine clearance less than 50 mL/min, unstable angina, acute coronary syndrome/congestive heart failure (New York Heart Association Functional Classification grade III or IV), ascites
11. Received any investigational therapy within 60 days of randomization
12. Blood donation within 56 days prior to randomization
13. Plasma donation within 7 days prior to randomization
14. Received luminal contrast agents such as barium or water-soluble oral contrast agent within 21 days prior to randomization
15. Known to have an impaired gag reflex, or prone to regurgitation or aspiration
16. Serious underlying disease that in the opinion of the investigator may interfere with the subject's ability to participate fully in the study
17. History of alcohol or drug abuse that in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures
18. Pregnant or lactating women
19. Prior enrolment in the current study and had received study treatment
20. Cognitive barriers that in the opinion of the investigator may interfere with the subject's ability to participate fully in the study
21. Inability to either read or understand English

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

46 participants in 2 patient groups

DCL-101

Experimental group

Treatment:

Drug: DCL-101 vs Golytely

GoLytely

Active Comparator group

Treatment:

Drug: DCL-101 vs Golytely